Barclays Reiterates an 'Underweight' on Paychex (PAYX); Just Dismal
Tweet Send to a FriendGet Alerts PAYX Hot Sheet
Price: $38.20 --0%
Rating Summary:
0 Buy, 9 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 8 | New: 6
Rating Summary:
0 Buy, 9 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 8 | New: 6
Trade PAYX Now!
Barclays reiterates an 'Underweight' on Paychex (NASDAQ: PAYX) price target of $30.00 (from $31.00).
Analyst, Gary E. Bisbee, finds shares of PAYX unattractive at current levels, saying the company's valuation is full, growth outlook is stalling and there's a lack of near-term catalysts...all that, but the company is well capitalized and profitable?!
Bisbee lowers FY13 EPS estimate from $1.62 to $1.60 after last night's in-line Q4 and weaker initial FY13 guidance.
For an analyst ratings summary and ratings history on Paychex click here. For more ratings news on Paychex click here.
Shares of Paychex closed at $31.93 yesterday, with a 52 week range of $25.12-$32.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Gary E. Bisbee, finds shares of PAYX unattractive at current levels, saying the company's valuation is full, growth outlook is stalling and there's a lack of near-term catalysts...all that, but the company is well capitalized and profitable?!
Bisbee lowers FY13 EPS estimate from $1.62 to $1.60 after last night's in-line Q4 and weaker initial FY13 guidance.
For an analyst ratings summary and ratings history on Paychex click here. For more ratings news on Paychex click here.
Shares of Paychex closed at $31.93 yesterday, with a 52 week range of $25.12-$32.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
